CompletedPhase 2NCT01118026
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Studying Classic Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Ann S. LaCasce, MD, MDDana-Farber Cancer Institute
- Intervention
- ABVD(drug)
- Enrollment
- 101 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2010 – 2021
Study locations (30)
- Naval Medical Center -San Diego, San Diego, California, United States
- Saint Helena Hospital, St. Helena, California, United States
- Beebe Medical Center, Lewes, Delaware, United States
- Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Weiss Memorial Hospital, Chicago, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
- Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States
- Memorial Hospital of South Bend, South Bend, Indiana, United States
- Cancer Center of Kansas - Wichita, Wichita, Kansas, United States
- Via Christi Regional Medical Center, Wichita, Kansas, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- Union Hospital of Cecil County, Elkton, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01118026 on ClinicalTrials.govOther trials for Classic Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07275216Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center
- RECRUITINGPHASE2NCT07209059PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin LymphomaNational Research Center for Hematology, Russia
- RECRUITINGPHASE2NCT06984146Nivo40-AVD for Advanced Classic Hodgkin LymphomaNational Medical Research Radiological Centre of the Ministry of Health of Russia
- RECRUITINGPHASE2NCT06745076Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE1, PHASE2NCT06642792A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaAkeso
- RECRUITINGPHASE2NCT06377540MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07234487Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT06812858PD-1 Inhibitors Maintenance for cHL Post-autoHCTSt. Petersburg State Pavlov Medical University